Nevro (NYSE:NVRO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Nevro (NYSE:NVRO - Free Report) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the medical equipment provider's stock.

NVRO has been the topic of several other reports. Piper Sandler raised Nevro from a "neutral" rating to an "overweight" rating and dropped their price target for the company from $6.00 to $5.85 in a research report on Friday, February 7th. Robert W. Baird upped their price target on Nevro from $5.00 to $6.00 and gave the company a "neutral" rating in a research report on Tuesday, November 12th. Truist Financial dropped their price target on Nevro from $7.00 to $4.70 and set a "hold" rating on the stock in a research report on Wednesday, December 18th. Royal Bank of Canada reissued a "sector perform" rating and set a $7.00 price target on shares of Nevro in a research report on Tuesday, November 12th. Finally, JMP Securities reissued a "market perform" rating on shares of Nevro in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $6.43.

Nevro Trading Up 0.1 %

Shares of Nevro stock traded up $0.01 on Tuesday, reaching $5.74. 692,309 shares of the company were exchanged, compared to its average volume of 1,257,277. The stock has a fifty day moving average price of $4.56 and a 200-day moving average price of $4.97. The firm has a market capitalization of $214.89 million, a price-to-earnings ratio of -3.03 and a beta of 0.91. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67. Nevro has a fifty-two week low of $3.16 and a fifty-two week high of $17.44.

Institutional Trading of Nevro

Several large investors have recently made changes to their positions in the stock. Two Sigma Investments LP boosted its stake in shares of Nevro by 39.9% during the 4th quarter. Two Sigma Investments LP now owns 219,319 shares of the medical equipment provider's stock worth $816,000 after acquiring an additional 62,568 shares in the last quarter. State of Wyoming boosted its stake in shares of Nevro by 55.6% during the 4th quarter. State of Wyoming now owns 31,043 shares of the medical equipment provider's stock worth $115,000 after acquiring an additional 11,091 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new stake in shares of Nevro during the 4th quarter worth about $136,000. Nuveen Asset Management LLC boosted its stake in shares of Nevro by 5.1% during the 4th quarter. Nuveen Asset Management LLC now owns 369,554 shares of the medical equipment provider's stock worth $1,375,000 after acquiring an additional 17,878 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its stake in Nevro by 20.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,803,532 shares of the medical equipment provider's stock valued at $6,709,000 after purchasing an additional 306,943 shares during the period. Institutional investors own 95.52% of the company's stock.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.